Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species
View / Open Files
Authors
Iljina, Marija
Hong, Liu
Horrocks, Mathew H
Ludtmann, Marthe H
Choi, Minee L
Hughes, Craig D
Ruggeri, Francesco S
Guilliams, Tim
Buell, Alexander K
Lee, Ji-Eun
Gandhi, Sonia
Lee, Steven F
Bryant, Clare E
Vendruscolo, Michele
Knowles, Tuomas P J
Dobson, Christopher M
De Genst, Erwin
Klenerman, David
Publication Date
2017-07-03Type
Article
Metadata
Show full item recordCitation
Iljina, M., Hong, L., Horrocks, M. H., Ludtmann, M. H., Choi, M. L., Hughes, C. D., Ruggeri, F. S., et al. (2017). Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species. https://doi.org/10.1186/s12915-017-0390-6
Abstract
Abstract
Background
The aggregation of the protein ɑ-synuclein (ɑS) underlies a range of increasingly common neurodegenerative disorders including Parkinson’s disease. One widely explored therapeutic strategy for these conditions is the use of antibodies to target aggregated ɑS, although a detailed molecular-level mechanism of the action of such species remains elusive. Here, we characterize ɑS aggregation in vitro in the presence of two ɑS-specific single-domain antibodies (nanobodies), NbSyn2 and NbSyn87, which bind to the highly accessible C-terminal region of ɑS.
Results
We show that both nanobodies inhibit the formation of ɑS fibrils. Furthermore, using single-molecule fluorescence techniques, we demonstrate that nanobody binding promotes a rapid conformational conversion from more stable oligomers to less stable oligomers of ɑS, leading to a dramatic reduction in oligomer-induced cellular toxicity.
Conclusions
The results indicate a novel mechanism by which diseases associated with protein aggregation can be inhibited, and suggest that NbSyn2 and NbSyn87 could have significant therapeutic potential.
Identifiers
External DOI: https://doi.org/10.1186/s12915-017-0390-6
This record's URL: https://www.repository.cam.ac.uk/handle/1810/265138
Rights
Rights Holder: Klenerman et al.